Oncology Today with Dr Neil Love

Dr. Neil Love
undefined
Nov 20, 2026 • 55min

GPRC5D-Directed Therapies for Multiple Myeloma — An Interview with Prof Rakesh Popat

Featuring an interview with Prof Rakesh Popat, including the following topics:Overview of GPRC5D and its clinical significance (0:00)Key findings from Phase II TALisman study regarding dysgeusia assessment for patients receiving talquetamab (2:30)Mitigating dysgeusia and dry mouth arising from GPRC5D-directed therapy (6:25)Key findings from the Phase III MonumenTAL-3 study (11:49)Selection factors for GPRC5D- and BCMA-directed therapies (15:16)Managing extramedullary multiple myeloma (MM) with GPRC5D-targeted therapies and beyond (18:30)Key findings with arlocabtagene autoleucel (arlo-cel) for relapsed/refractory (R/R) MM (20:47)Ramantamig and other GPRC5D-targeted approaches (25:32)Comparing arlo-cel to ciltacabtagene autoleucel for MM; CNS issues with GPRC5D-directed therapies (28:42)Case: A man in his late 70s with a history of chronic obstructive pulmonary disease and t(4;14) R/R MM who receives fourth-line talquetamab and attains a very good partial response (38:27)Cases: A man in his late 40s with t(11;14), del(17p) R/R MM who enrolls in the Phase II QUINTESSENTIAL-2 study for third-line treatment; a man in his late 60s with t(11;14), del(17p) MM and early relapse after third-line autologous stem cell transplant (45:18)Guidance on sequencing BCMA- and GPRC5D-directed therapies (47:35)Importance of tumor debulking; access to arlo-cel (52:27)CME information and select publications
undefined
Nov 16, 2026 • 16min

Novel Therapies for Non-Hodgkin Lymphoma — Microlearning Activity 3: An Interview with Dr Matthew Lunning on the Utility of Tafasitamab

Dr Matthew Lunning, a Fred and Pamela Buffett Cancer Center medical oncologist specializing in lymphoma, discusses tafasitamab across follicular lymphoma and diffuse large B-cell lymphoma. Topics include tafasitamab-lenalidomide versus epcoritamab, the FrontMIND trial, treatment considerations for frail or elderly patients, dosing, infection concerns, and CD19 antibody use before CAR T-cell therapy.
undefined
Nov 13, 2026 • 58min

Follicular Lymphoma — Where We Are, Where We're Headed in the Use of Bispecific Antibodies

Matthew Matasar, a Rutgers lymphoma specialist, and Chan Chea, an Australian hematology-oncology professor, explore the rapidly evolving role of bispecific antibodies in follicular lymphoma. They discuss T-cell engagement, second-line treatment, bispecifics versus CAR T, infection and neurologic complications, and promising agents such as surovatamig. The conversation also looks ahead to first-line therapy, multispecific antibodies, and next-generation immune strategies.
undefined
Nov 11, 2026 • 1h 2min

Relapsed/Refractory Multiple Myeloma — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute

Sagar Lonial, a Winship myeloma specialist, and Paul G Richardson, a Dana-Farber therapeutics investigator, explore the fast-changing landscape of relapsed/refractory multiple myeloma. They discuss CAR T-cell therapy, bispecific antibodies, belantamab and other antibody-drug conjugates, treatment sequencing, resistance, aggressive extramedullary relapse, and emerging cereblon modulators in frontline and relapsed disease.
undefined
Nov 10, 2026 • 59min

Prostate Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute

Emmanuel S Antonarakis, a University of Minnesota prostate cancer researcher, and Neeraj Agarwal, a Dana-Farber specialist in advanced disease, discuss modern treatment strategies. Topics include endocrine therapy, PARP inhibitors, AKT blockade for PTEN-deficient tumors, PSMA-targeted radiopharmaceuticals, MSI-high disease, and treatment choices after lutetium.
undefined
Nov 9, 2026 • 2h 22min

Breast Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute

Charles E. Geyer Jr., Maryam Lustberg, Rita Nanda, and Seth Wander, leading breast cancer oncologists and researchers, explore major advances across ER-positive, HER2-positive, and triple-negative disease. Topics include oral SERDs, CDK4/6 inhibitors, ctDNA-guided care, ADC sequencing, HER2 treatment strategies, immunotherapy, and supportive care.
undefined
Nov 6, 2026 • 18min

Novel Therapies for Non-Hodgkin Lymphoma — Microlearning Activity 2: An Interview with Dr Matthew Lunning on Novel Combination Regimens

Dr Matthew Lunning, a lymphoma specialist and clinical investigator at the Fred and Pamela Buffett Cancer Center, explores cutting-edge treatment combinations for non-Hodgkin lymphoma. He discusses bispecific antibodies and antibody-drug conjugates in relapsed disease, options for patients avoiding CAR T-cell therapy, and treatment decisions for very elderly people with mantle cell lymphoma. The conversation also covers TP53 risk, blastoid disease, BCL2 combinations, and MRD-guided care.
undefined
Nov 4, 2026 • 1h 2min

Diffuse Large B-Cell Lymphoma — A Grand Rounds Program

Matthew Matasar, Chief of Blood Disorders at Rutgers Cancer Institute, explores evolving treatment strategies for diffuse large B-cell lymphoma. He discusses first-line choices, POLARIX and FrontMIND, plus the growing roles of CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates in relapsed disease. The conversation also covers treatment sequencing, CNS activity, cell-free DNA, and managing key toxicities.
undefined
Nov 2, 2026 • 18min

Novel Therapies for Non-Hodgkin Lymphoma — Microlearning Activity 1: An Interview with Dr Matthew Lunning on CNS Prophylaxis

Dr Matthew Lunning, a medical oncologist specializing in lymphoma and cellular therapy, discusses a high-risk DLBCL case in an older woman. Topics include pola-R-CHP, POLARIX and cell-of-origin testing, assessing CNS relapse risk, CSF evaluation, intrathecal methotrexate, and adapting treatment for frail adults. He also shares practical experience with the Polar Bear regimen.
undefined
Oct 29, 2026 • 1h 1min

Hormone Receptor-Positive Localized Breast Cancer — A Grand Rounds Activity

Dr Erica Mayer, a Dana-Farber medical oncologist and breast cancer investigator, explores personalized care for localized hormone receptor-positive breast cancer. Topics include genomic assays for chemotherapy decisions, late-recurrence testing, adjuvant CDK4/6 inhibitors, toxicity management, and emerging oral SERDs. She also addresses treatment selection, endocrine therapy intolerance, and the evolving role of genomic testing in neoadjuvant care.

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app